NEW YORK, Dec. 26, 2017 —
WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on AMRN, IONS, ENDP, and TEVA which can be accessed for free by signing up to http://www.wallstequities.com/registration. Featured this morning on WallStEquities.com are the following Drug Manufacturers stocks: Amarin Corp. PLC (NASDAQ: AMRN), Ionis Pharmaceuticals Inc. (NASDAQ: IONS), Endo International PLC (NASDAQ: ENDP), and Teva Pharmaceutical Industries Ltd (NYSE: TEVA). The Pharmaceutical and Medicine Manufacturing industry develops and produces a variety of medicinal and other health-related products that save the lives of millions of people from various diseases and permits many people suffering from illness to recover to lead productive lives. All you have to do is sign up today for this free limited time offer, click the link below. http://www.wallstequities.com/registration
Dublin, Ireland-based Amarin Corp. PLC's shares recorded a trading volume of 1.91 million shares last Friday, which was above their three months average volume of 1.41 million shares. The stock finished the trading session 3.28% higher at $4.09. The Company's shares have gained 21.73% in the last one month, 19.24% over the previous three months, and 32.79% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 20.98% and 22.60%, respectively. Furthermore, shares of Amarin, which focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the US, have a Relative Strength Index (RSI) of 77.47.
On December 18th, 2017, Amarin announced that John F. Thero, President and CEO, is scheduled to present a general Company update at the 36th Annual J.P. Morgan Healthcare Conference on January 10th, 2018, at 8:00 p.m. EST in San Francisco. A live audio webcast of the presentation will be available on the Company's website. Get the full research report on AMRN for free by clicking below at: http://www.wallstequities.com/registration/?symbol=AMRN
On Friday, Carlsbad, California headquartered Ionis Pharmaceuticals Inc.'s stock ended the session 1.05% lower at $50.86. A total volume of 643,776 shares was traded. The Company's shares have gained 6.33% on an YTD basis. The stock is trading 0.97% above its 200-day moving average. Moreover, shares of Ionis Pharma, which focuses on developing drugs for patients with severe and rare diseases, have an RSI of 42.20.
On December 15th, 2017, Ionis Pharma announced that its management will present a Company overview at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 08th, 2018, at 7:30 a.m. PT in San Francisco, California. A live audio webcast of the presentation will be available under the “Investors & Media” section of the Company's website. The free technical report on IONS can be accessed at: http://www.wallstequities.com/registration/?symbol=IONS
Dublin, Ireland headquartered Endo International PLC's stock ended the day 2.38% lower at $7.81 with a total trading volume of 3.63 million shares. The Company's shares have gained 2.36% in the last month. The stock is trading 7.76% above its 50-day moving average. Additionally, shares of Endo, which develops, manufactures, and distributes pharmaceutical products and devices worldwide, have an RSI of 53.50.
On December 12th, 2017, research firm Guggenheim initiated a 'Neutral' rating on the Company's stock, with a target price of $8.50 per share. Sign up for free on Wall St. Equities and claim the latest report on ENDP at: http://www.wallstequities.com/registration/?symbol=ENDP
Teva Pharmaceutical Industries
Shares in Petach Tikva, Israel headquartered Teva Pharmaceutical Industries Ltd recorded a trading volume of 16.12 million shares. The stock ended Friday's session 1.35% higher at $18.75. The Company's shares have gained 39.09% in the last month and 9.20% over the previous three months. The stock is trading above its 50-day moving average by 30.10%. Furthermore, shares of Teva Pharma, which develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide, have an RSI of 67.62.
On December 15th, 2017, research firm Morgan Stanley upgraded the Company's stock rating from 'Underweight' to 'Equal-Weight'.
On December 15th, 2017, Teva Pharma announced the exclusive launch of generic Viread®1 (tenofovir disoproxil fumarate) tablets 300 mg in the US Tenofovir disoproxil fumarate tablets are a nucleotide analog HIV-1 reverse transcriptase inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients two years of age and older. See the free research coverage on TEVA at: http://www.wallstequities.com/registration/?symbol=TEVA
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Wall St. Equities
Latest posts by Brad Bennett (see all)
- Standard Lithium Provides California Lithium Exploration Update - February 20, 2018
- TRI Pointe Group, Inc. Reports 2017 Fourth Quarter and Full Year Results and Announces New Stock Repurchase Program - February 20, 2018
- FanWide Wins the HYPE Sports Innovation Global Competition - February 20, 2018